EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella

Funding from EDCTP will allow testing of a novel whole-cell inactivated oral vaccine in clinical trials in Europe and Africa

EVI and Hilleman Laboratories today announced that a multidisciplinary, international consortium coordinated by EVI has now received support from the European and Developing Countries Clinical Trials Partnership (EDCTP) to advance a safe, efficacious and affordable Shigella vaccine being developed by Hilleman Laboratories. The project will be funded by EDCTP through a grant of €8.6 million.

For full news release please see following link.